Kim, Mi Joung <br/><br/>
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.  [electronic resource] 

 -  Anticancer research  Aug 2012 
 - 3161-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Benzenesulfonates--pharmacology<br/>Carcinoma, Renal Cell--genetics<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Enzyme-Linked Immunosorbent Assay<br/>Flow Cytometry<br/>Histone Deacetylase Inhibitors--pharmacology<br/>Humans<br/>Hydroxamic Acids--pharmacology<br/>Kidney Neoplasms--genetics<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Pyridines--pharmacology<br/>Sorafenib<br/>Sulfonamides<br/>Von Hippel-Lindau Tumor Suppressor Protein--genetics<br/>Vorinostat